Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Free Cash Flow: 2010-2025

Historic Free Cash Flow for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $156.9 million.

  • Arrowhead Pharmaceuticals' Free Cash Flow rose 108.03% to $13.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $156.9 million, marking a year-over-year increase of 125.96%. This contributed to the annual value of $156.9 million for FY2025, which is 125.96% up from last year.
  • Arrowhead Pharmaceuticals' Free Cash Flow amounted to $156.9 million in FY2025, which was up 125.96% from -$604.3 million recorded in FY2024.
  • Arrowhead Pharmaceuticals' 5-year Free Cash Flow high stood at $156.9 million for FY2025, and its period low was -$604.3 million during FY2024.
  • Over the past 3 years, Arrowhead Pharmaceuticals' median Free Cash Flow value was -$330.6 million (recorded in 2023), while the average stood at -$259.4 million.
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Free Cash Flow surged by 237.11% in 2021 and then crashed by 227.86% in 2022.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Free Cash Flow (Yearly) stood at $147.7 million in 2021, then crashed by 227.86% to -$188.9 million in 2022, then crashed by 75.02% to -$330.6 million in 2023, then plummeted by 82.78% to -$604.3 million in 2024, then soared by 125.96% to $156.9 million in 2025.